DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market
Some of the key facts of the Metastatic Prostate Cancer Market Report:
The metastatic prostate cancer market size is estimated at approximately USD 11,500 million in 2025 and is projected to grow at a significant CAGR during 2026–2036.
In June 2025, Johnson & Johnson, a US-based pharmaceutical firm, has released Phase I trial data for its bispecific antibody, pasritamig, targeting metastatic castration-resistant prostate cancer (mCRPC). The first-in-human study involved 174 participants aged 36 to 89, who had previously received an average of four treatments. Findings from the trial showed that pasritamig was well-tolerated and exhibited promising anti-tumor activity in patients with mCRPC.
In May 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 as part of the ongoing first-in-human ENGAGER-PSMA-01 clinical trial, targeting patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial is designed to evaluate the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of JANX007, either as a monotherapy or in combination therapy, in adult patients with advanced mCRPC. The initial Phase Ib segment will enroll taxane-naïve mCRPC patients, focusing on those in first-line (1L) and second-line (2L) treatment settings. Two dosing regimens—0.3/2/6mg and 0.3/2/9mg—of JANX007 monotherapy are being assessed for their safety and effectiveness.
In May 2025, Astellas and Pfizer have shared five-year follow-up results from the open-label extension of the Phase III ARCHES trial. The findings revealed that Xtandi (enzalutamide), when used in combination with androgen deprivation therapy (ADT), led to a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC). Patients receiving this combination therapy demonstrated improved survival outcomes compared to those treated with placebo plus ADT.
In March 2025, The FDA has granted approval to Novartis’ radioligand therapy, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable candidates for postponing chemotherapy.
In March 2025, MacroGenics is discontinuing the development of one of its antibody-drug conjugates (ADC) following disappointing results in a Phase II prostate cancer study. The Rockville, Maryland-based biotech announced that trials of vobramitamab duocarmazine (vobra duo) will be halted, as the safety and efficacy data from the TAMARACK Phase II study (NCT05551117) did not justify further financial investment.
In March 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial targeting advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial aims to evaluate the tolerability, pharmacodynamics, safety, preliminary efficacy, and pharmacokinetics of JANX007 as a standalone treatment or in combination therapy for adults with advanced mCRPC.
According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of metastatic prostate cancer in the 7MM were ~315,000.
Based on DelveInsight’s assessment in 2025, the US had ~3,864,000 prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2026−2036).
The five-year prevalent cases of prostate cancer in the US was approximately ~1,157,000 in 2025.
In 2025, in the US, the total cases of mCSPC were approximately ~72,500.
According to the SEER, prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years. The most number of cases was found in people aged between 65 and 74 years, followed by 55–64 years and 75–84 years.
The market is experiencing strong expansion in genomically targeted therapies, particularly PARP inhibitors such as Olaparib (LYNPARZA), Talazoparib (TALZENNA), and the combination of abiraterone acetate/niraparib (AKEEGA) for patients with HRR/BRCA-mutated metastatic castration-resistant prostate cancer. Concurrently, the growing adoption of molecular diagnostics and PSMA imaging is enhancing patient stratification and is expected to further accelerate the uptake of targeted treatment options over the forecast period.
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.
Metastatic Prostate Cancer Overview
Metastatic prostate cancer is an advanced stage of prostate cancer in which the cancer cells have spread beyond the prostate gland to other parts of the body, most commonly the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system. Symptoms may include bone pain, fatigue, weight loss, and difficulty urinating. While it is not curable, treatments like hormone therapy, chemotherapy, targeted therapy, and radiation can help manage symptoms and slow disease progression.
To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast
Metastatic Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Metastatic Prostate Cancer Epidemiology Segmentation:
The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Prevalent Cases of Prostate Cancer
Five-year Prevalent Cases of Prostate Cancer
Total Prevalent Cases of Prostate Cancer Cases by Clinical Stages
Age-specific Cases of Prostate Cancer
Total Prevalent Cases of Metastatic Prostate Cancer
Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast
Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Metastatic Prostate Cancer Therapies and Key Companies
177Lu-PSMA-I&T: Curium US LLC
Darolutamide (Nubeqa, BAY1841788): Bayer
HB-302/HB-301: Hookipa Biotech GmbH
Enzalutamide: University Health Network
Opevesostat: Merck Sharp & Dohme
Pembrolizumab: Merck Sharp & Dohme
ARV-766 Part A&B: Arvinas Androgen Receptor
Darolutamide: UNICANCER
Apalutamide: Aragon Pharmaceuticals
REGN2810: Mark Stein
177Lu-PSMA-617: Novartis
ODM-208: Orion Corporation, Orion Pharma
Apalutamide: Janssen Research & Development
AZD0754: AstraZeneca
Enzalutamide: MedSIR
Niraparib: Janssen Research & Development
177Lu-DOTA-rosopatamb: Telix Pharmaceuticals
Darolutamide: Alliance Foundation Trials
Tazemetostat: Epizyme, Inc.
Cabozantinib: Exelixis
Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape
Metastatic Prostate Cancer Market Drivers
Rising incidence of prostate cancer and an aging population are increasing the number of patients progressing to metastatic disease.
Advancements in targeted therapies, androgen receptor inhibitors, radioligand therapies, and immunotherapies are expanding treatment options and improving outcomes.
Growing adoption of precision medicine and biomarker-based testing is enabling more personalized treatment approaches.
Increased awareness, early diagnosis, and improved screening practices are supporting better disease management.
Metastatic Prostate Cancer Market Barriers
High treatment costs associated with advanced therapies may limit patient access and place pressure on healthcare systems.
Development of treatment resistance, particularly in metastatic castration-resistant prostate cancer (mCRPC), remains a significant clinical challenge.
Adverse effects and safety concerns linked to long-term therapy can affect treatment adherence.
Stringent regulatory requirements and lengthy clinical development timelines may delay the introduction of new therapies.
Scope of the Metastatic Prostate Cancer Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement
To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Metastatic Prostate Cancer Market Report Introduction
2. Executive Summary for Metastatic Prostate Cancer
3. SWOT analysis of Metastatic Prostate Cancer
4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance
5. Metastatic Prostate Cancer Market Overview at a Glance
6. Metastatic Prostate Cancer Disease Background and Overview
7. Metastatic Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Prostate Cancer
9. Metastatic Prostate Cancer Current Treatment and Medical Practices
10. Metastatic Prostate Cancer Unmet Needs
11. Metastatic Prostate Cancer Emerging Therapies
12. Metastatic Prostate Cancer Market Outlook
13. Country-Wise Metastatic Prostate Cancer Market Analysis (2022–2036)
14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies
15. Metastatic Prostate Cancer Market Drivers
16. Metastatic Prostate Cancer Market Barriers
17. Metastatic Prostate Cancer Appendix
18. Metastatic Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
